<div id="readability-page-1"><p>In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Amylyx Pharmaceuticals Inc, with a price target of <span id="expert-recommendation-target">$24.00</span>.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>According to TipRanks, Katkhuda is a 5-star analyst with an average return of <span>30.9%</span> and a 52.19% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Viridian Therapeutics, and Dianthus Therapeutics.</p> <p>In a report released on May 11, Guggenheim also reiterated a Buy rating on the stock with a $30.00 price target.</p></div>

AMLX

LABU

SBIO

<p>LifeSci Capital analyst Rami Katkhuda has maintained a Buy rating on Amylyx Pharmaceuticals Inc (AMLX) with a price target of $24.00. Katkhuda, a 5-star analyst, has an average return of 30.9% and a success rate of 52.19%. Guggenheim also reiterated a Buy rating with a $30.00 price target.</p>

Tip Ranks

Amylyx Pharmaceuticals

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

iShares US Pharma

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

VanEck Biotech ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

Viridian Therapeutics

Dianthus Therapeutics

LifeSci Capital Remains a Buy on Amylyx Pharmaceuticals Inc (AMLX)